News from Samsara Vision

March 16, 2022 Posted by Samsara Vision

 

Samsara Vision, a company focused on bringing vision and freedom back to late-stage, age-related macular degeneration (AMD) patients through advanced visual prosthetic devices, announced that the German Institute for Hospital Remuneration (InEK) has granted NUB (Neue Untersuchungs- und Behandlungsmethoden) Status 1 reimbursement designation for the SING IMT™ (smaller-incision new-generation implantable miniature telescope).The SING IMT is approved for people living with late-stage, age-related macular degeneration (AMD) who are 55 years of age or older CE Referenced Countries since May 2020.

The NUB process allows negotiations between participating hospitals and health insurance providers regarding supplemental reimbursement of new medical treatments with the potential to improve the standard of care for patients in Germany.

Nearly invisible inside the eye, the tiny SING IMT is a Galilean telescope implant designed to improve visual acuity and quality of life for patients with late-stage, age-related macular degeneration. Comprised of ultra-precision micro-optics, the SING IMT is implanted during typical, out-patient cataract surgery. After recovering from surgery, the patients work closely with a low vision specialist and occupational therapists to learn how to use their new vision.

AMD is the leading cause of blindness in older adults. It is a progressive disease that, for some, will create a blind spot that is uncorrectable by glasses, drugs, injections or cataract surgery. Other currently available treatments for late-stage AMD, such as intraocular injections, may slow or delay the progression of the disease but do not have a direct effect in regaining vision that SING IMT offers to eligible candidates.

“We look forward to working with hospitals and physicians across Germany to offer their patients the most innovative treatment for late-stage AMD,” said Jason Herod, Chief Commercial Officer, Europe, Samsara Vision. “We’ve already established several partnerships and are building our referral network to help bring our novel technology to people who are living with blind spots caused by AMD that restricts their ability to see the people they love and participate in the activities they enjoy. We hope that the SING IMT offers hope to people living with late-stage AMD.”

About SING IMT

Because AMD is a progressive disease, over time, patients have adapted with the loss of vision in the central field of vision. Before receiving the SING IMT, patients must understand the possible and realistic outcomes post-op and commit to working with their ophthalmological team to use visual techniques and exercises to maximize the effectiveness of SING IMT. Patients must also meet age, vision, cornea health, and other requirements noted in the Patient Information Booklet to determine if they are a candidate for the SING IMT.

The telescopic implant is not a cure for late-stage age-related macular degeneration (AMD). It will not return your vision to the level a patient had before AMD, nor will it completely make up for vision loss. The most common risks of the SING IMT surgery include inflammatory deposits or precipitates on the device and increased intraocular pressure. Significant adverse events include corneal edema, vision-impairing corneal edema, corneal transplant, and decrease in visual acuity. There is a risk that having the telescope implantation surgery could worsen your vision rather than improve it. Individual results may vary.

The SING IMT is approved for late-stage AMD patients who are 55 years of age or older CE Referenced Countries and is not currently FDA approved in the United States.

To learn more about SING IMT, visit http://singimt.samsaravision.com

Next entry: CORE expands specialty contact lens expertise

Previous entry: Change at the top of TRIOPTICS

Leave a comment:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

Submit the word you see below: